Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER_GOV × lorlatinib × Clear all

Phase

Status

Sponsor Class

OTHER 27 INDUSTRY 18 NETWORK 2 OTHER_GOV 1 NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 43 Capecitabine 40 Radiotherapy 31 Gemcitabine 31 Paclitaxel 30 Oxaliplatin 30 Drug Therapy 29 Cyclophosphamide 29 Carboplatin 28 apatinib 27 tislelizumab 25 Irinotecan 25 Docetaxel 25 Fluorouracil 24 Bevacizumab 23 Surgical Procedures, Operative 19 Nivolumab 18 pembrolizumab 17 fludarabine 16 Metformin 16 Radiation 15 Exercise 15 camrelizumab 14 Blood Specimen Collection 14 S 1 (combination) 13 Control Groups 12 Neoadjuvant Therapy 11 Trastuzumab 10 Standard of Care 10 Pemetrexed 10

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03612154 2022-04-06

Study of Lorlatinib in ROS1 Rearranged NSCLC

National Cancer Center, Korea

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡